Juno Therapeutics Inc (NASDAQ:JUNO) shares saw strong trading volume on Friday . 12,479,353 shares traded hands during trading, an increase of 475% from the previous session’s volume of 2,170,435 shares.The stock last traded at $27.98 and had previously closed at $40.82.

Several equities analysts have commented on the company. Leerink Swann reiterated an “outperform” rating and set a $60.00 price target on shares of Juno Therapeutics in a report on Friday. JPMorgan Chase & Co. downgraded shares of Juno Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $63.00 to $39.00 in a research note on Friday. FBR & Co lowered their price objective on shares of Juno Therapeutics from $73.00 to $61.00 and set an “outperform” rating on the stock in a research note on Friday. Barclays PLC initiated coverage on shares of Juno Therapeutics in a research note on Wednesday. They issued an “equal weight” rating and a $48.00 price objective on the stock. Finally, Vetr upgraded shares of Juno Therapeutics from a “buy” rating to a “strong-buy” rating and set a $54.66 price objective on the stock in a research note on Wednesday, June 8th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $53.11.

The company’s market capitalization is $2.81 billion. The stock’s 50-day moving average price is $41.76 and its 200 day moving average price is $38.56.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.26. The firm earned $9.80 million during the quarter, compared to the consensus estimate of $4.83 million. During the same quarter in the prior year, the company posted ($0.30) EPS. Equities analysts anticipate that Juno Therapeutics Inc will post ($2.22) EPS for the current year.

In related news, CFO Steve Harr sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $43.32, for a total transaction of $1,299,600.00. Following the transaction, the chief financial officer now directly owns 716,052 shares of the company’s stock, valued at approximately $31,019,372.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Hans Edgar Bishop sold 90,750 shares of the business’s stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $46.42, for a total value of $4,212,615.00. Following the transaction, the chief executive officer now directly owns 2,704,609 shares in the company, valued at $125,547,949.78. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its position in shares of Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock worth $2,252,000 after buying an additional 10,884 shares in the last quarter. US Bancorp DE raised its position in shares of Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock worth $3,900,000 after buying an additional 1,600 shares in the last quarter. BBR Partners LLC purchased a new position in shares of Juno Therapeutics during the fourth quarter worth approximately $1,539,000. Baillie Gifford & Co. purchased a new position in shares of Juno Therapeutics during the fourth quarter worth approximately $12,312,000. Finally, Stevens Capital Management LP purchased a new position in shares of Juno Therapeutics during the fourth quarter worth approximately $2,315,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.